当前位置：
X-MOL 学术
›
Drug Des. Dev. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
Drug Design, Development and Therapy ( IF 4.7 ) Pub Date : 2020-08-25 , DOI: 10.2147/dddt.s248850 Kai-Cai Liu 1 , Ying-Hong Hao 2 , Wei-Fu Lv 2 , Wei-Dong Jia 3 , Chu-Shu Ji 4 , Chun-Ze Zhou 2 , De-Lei Cheng 2 , Shao-Bao Xu 1 , Zong-Gen Gao 1 , Ming-Xue Su 1 , Chang-Sheng Shi 1
Drug Design, Development and Therapy ( IF 4.7 ) Pub Date : 2020-08-25 , DOI: 10.2147/dddt.s248850 Kai-Cai Liu 1 , Ying-Hong Hao 2 , Wei-Fu Lv 2 , Wei-Dong Jia 3 , Chu-Shu Ji 4 , Chun-Ze Zhou 2 , De-Lei Cheng 2 , Shao-Bao Xu 1 , Zong-Gen Gao 1 , Ming-Xue Su 1 , Chang-Sheng Shi 1
Affiliation
Purpose: Transcatheter arterial chemoembolization (TACE) and targeted therapy have become common methods in the treatment of advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC.
Methods: The clinical data of 75 patients with BCLC stage C HCC who received TACE-sorafenib or TACE as the initial treatment were retrospectively analyzed. Tumor response, time to progression (TTP), overall survival (OS), and adverse events were compared at 1 month after surgery in the two groups.
Results: One month after treatment, the disease control rate in the TACE-sorafenib group was higher than that in the TACE group alone (82.76% and 57.50%, respectively, P = 0.018). The median values of TTP and OS in the TACE-sorafenib group were longer than those in the TACE group (TTP was 7.6 and 3.4 months, respectively, P = 0.002; OS was 13.6 and 6.3 months, respectively, P = 0.041). The cumulative survival time at 3 months, 6 months, and 1 year was higher in the TACE-sorafenib group than in the TACE group (83.5%, 71.2%, 45.7% vs 57.4%, 40.6%, 21.2%). Sorafenib-related side effects such as hypertension, hand-foot syndrome, and oral ulcers were more common than those in the TACE group alone (P< 0.05).
Conclusion: Compared with TACE treatment alone, TACE combined with sorafenib in BCLC-C stage HCC significantly improved disease control rate, TTP, and OS, and no significant increase in adverse reactions was observed.
Keywords: hepatocellular carcinoma, TACE, sorafenib, survival
中文翻译：
经动脉化疗栓塞联合索拉非尼治疗 BCLC C 期肝细胞癌患者。
目的：经导管动脉化疗栓塞（TACE）和靶向治疗已成为晚期肝细胞癌（HCC）治疗的常用方法。本研究旨在评估 TACE 联合索拉非尼（TACE-索拉非尼）和单独 TACE 治疗巴塞罗那临床 C 期 HCC 的安全性和有效性。
方法：回顾性分析接受TACE-索拉非尼或TACE作为初始治疗的75例BCLC C期HCC患者的临床资料。比较两组术后1个月的肿瘤反应、进展时间（TTP）、总生存期（OS）和不良事件。
结果：治疗1个月后，TACE联合索拉非尼组的疾病控制率高于单纯TACE组（分别为82.76%和57.50%，P=0.018）。TACE-索拉非尼组的 TTP 和 OS 中位值均长于 TACE 组（TTP 分别为 7.6 和 3.4 个月，P = 0.002；OS 分别为 13.6 和 6.3 个月，P = 0.041）。TACE-索拉非尼组3个月、6个月和1年的累积生存时间高于TACE组（83.5%、71.2%、45.7% vs 57.4%、40.6%、21.2%）。索拉非尼相关的高血压、手足综合征、口腔溃疡等副作用较单纯 TACE 组更常见（P<0.05）。
结论：与单纯 TACE 治疗相比，TACE 联合索拉非尼治疗 BCLC-C 期 HCC 可显着提高疾病控制率、TTP 和 OS，且不良反应未见明显增加。
关键词：肝细胞癌，TACE，索拉非尼，生存期
更新日期：2020-08-25
Methods: The clinical data of 75 patients with BCLC stage C HCC who received TACE-sorafenib or TACE as the initial treatment were retrospectively analyzed. Tumor response, time to progression (TTP), overall survival (OS), and adverse events were compared at 1 month after surgery in the two groups.
Results: One month after treatment, the disease control rate in the TACE-sorafenib group was higher than that in the TACE group alone (82.76% and 57.50%, respectively, P = 0.018). The median values of TTP and OS in the TACE-sorafenib group were longer than those in the TACE group (TTP was 7.6 and 3.4 months, respectively, P = 0.002; OS was 13.6 and 6.3 months, respectively, P = 0.041). The cumulative survival time at 3 months, 6 months, and 1 year was higher in the TACE-sorafenib group than in the TACE group (83.5%, 71.2%, 45.7% vs 57.4%, 40.6%, 21.2%). Sorafenib-related side effects such as hypertension, hand-foot syndrome, and oral ulcers were more common than those in the TACE group alone (P< 0.05).
Conclusion: Compared with TACE treatment alone, TACE combined with sorafenib in BCLC-C stage HCC significantly improved disease control rate, TTP, and OS, and no significant increase in adverse reactions was observed.
Keywords: hepatocellular carcinoma, TACE, sorafenib, survival
中文翻译：
经动脉化疗栓塞联合索拉非尼治疗 BCLC C 期肝细胞癌患者。
目的：经导管动脉化疗栓塞（TACE）和靶向治疗已成为晚期肝细胞癌（HCC）治疗的常用方法。本研究旨在评估 TACE 联合索拉非尼（TACE-索拉非尼）和单独 TACE 治疗巴塞罗那临床 C 期 HCC 的安全性和有效性。
方法：回顾性分析接受TACE-索拉非尼或TACE作为初始治疗的75例BCLC C期HCC患者的临床资料。比较两组术后1个月的肿瘤反应、进展时间（TTP）、总生存期（OS）和不良事件。
结果：治疗1个月后，TACE联合索拉非尼组的疾病控制率高于单纯TACE组（分别为82.76%和57.50%，P=0.018）。TACE-索拉非尼组的 TTP 和 OS 中位值均长于 TACE 组（TTP 分别为 7.6 和 3.4 个月，P = 0.002；OS 分别为 13.6 和 6.3 个月，P = 0.041）。TACE-索拉非尼组3个月、6个月和1年的累积生存时间高于TACE组（83.5%、71.2%、45.7% vs 57.4%、40.6%、21.2%）。索拉非尼相关的高血压、手足综合征、口腔溃疡等副作用较单纯 TACE 组更常见（P<0.05）。
结论：与单纯 TACE 治疗相比，TACE 联合索拉非尼治疗 BCLC-C 期 HCC 可显着提高疾病控制率、TTP 和 OS，且不良反应未见明显增加。
关键词：肝细胞癌，TACE，索拉非尼，生存期
京公网安备 11010802027423号